EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optical Genome Mapping Is a Powerful Diagnostic Tool in Non-Hodgkin Lymphoma

Amber Verhasselt, Geneviève Ameye, Justine Vanhevel, Thomas Tousseyn, Johanna Vets, Esther Hauben, Peter Meeus, Marlies Vanden Bempt, Koen Debackere, Robert A Forsyth, Luuk Harbers, Jonas Demeulemeester und 4 weitere

Modern Pathology · 2026

DOI: 10.1016/j.modpat.2025.100951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026. Verfasst von Amber Verhasselt und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Genetics of Malignant Disorders, Department of Human Genetics, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin, Chromosome Mapping, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KU Leuven, King Baudouin Foundation, Research Foundation Flanders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-Hodgkin lymphoma (NHL) is a diverse and heterogeneous group of hematological malignancies. These lymphomas arise from the clonal proliferation of either B/T or natural killer lymphocytes, and their correct classification relies partly on identifying characteristic structural variants and copy number alterations. Current standard-of-care technologies for detecting these genomic features, chromosome banding analysis (CBA) and fluorescent in situ hybridization (FISH), are labor intensive and have specific limitations. CBA has low resolution and relies on viable cell culture, whereas the targeted approach of FISH does not provide the whole genome view required for comprehensive disease characterization. This highlights the need for higher-resolution nontargeted genomic methods. Previous studies have evaluated optical genome mapping (OGM) as a whole genome alternative for cytogenomic characterization in NHL diagnostics but were restricted in number and to cases with peripheral blood and/or bone marrow invasion. Here, we selected a comprehensive cohort of 110 NHL cases (79 B-NHL and 31 T-NHL/natural killer-NHL) derived from different types of tissue biopsies, all with established histopathological diagnoses. Seventy-eight samples were genomically well characterized at diagnosis by CBA and FISH. The remaining 32 cases were included because of previous CBA failure, although FISH data were available for 20 cases. OGM provided informative results in 94% of the cohort, with a high concordance rate of 97.6% compared with CBA/FISH in detecting clinically relevant aberrations. The 2 variants that were missed were both present at the detection threshold of OGM. In contrast, OGM successfully resolved 26 samples with previous CBA failure and detected 3 additional disease-defining events, resulting in diagnostic reclassification of 1 patient. Finally, OGM identified novel recurrent aberrations that warrant further investigation into their pathogenetic implications. To conclude, OGM robustly detects clinically relevant structural variants and copy number alterations and presents a promising alternative to CBA and FISH in routine diagnostic evaluation of NHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Non-HodgkinChromosome MappingBiomarkers, TumorHumansIn Situ Hybridization, FluorescenceFemaleMaleMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

chromosome banding analysiscytogenomic diagnosisfluorescent in situ hybridizationnon-Hodgkin lymphomaoptical genome mapping

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory for Genetics of Malignant Disorders, Department of Human Genetics, KU Leuven, Leuven, Belgium.
  • Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
  • Department of Pathology, University Hospitals Leuven, Leuven, Belgium; Laboratory for Translational Cell and Tissue Research, Department of Imaging & Pathology, KU Leuven, Leuven, Belgium.
  • Laboratory for Translational Cell and Tissue Research, Department of Imaging & Pathology, KU Leuven, Leuven, Belgium.
  • Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
  • Laboratory of Experimental Hematology, Department of Oncology, KU Leuven, Leuven, Belgium; LKI-Leuven Cancer Institute, KU Leuven - University Hospitals Leuven, Leuven, Belgium.

Förderung

  • KU Leuven
  • King Baudouin Foundation
  • Research Foundation Flanders
  • Universitaire Ziekenhuizen Leuven, KU Leuven
  • Vlaamse regering
  • Vermont Studio Center
  • Vlaams Supercomputer Centrum
  • Belgian American Educational Foundation Inc

Zitieren

APA

Verhasselt, A., Ameye, G., Vanhevel, J., Tousseyn, T., Vets, J., Hauben, E., Meeus, P., Bempt, M. V., Debackere, K., Forsyth, R. A., Harbers, L., Demeulemeester, J., Michaux, L., Rack, K., Dewaele, B., & De Bie, J. (2026). Optical Genome Mapping Is a Powerful Diagnostic Tool in Non-Hodgkin Lymphoma. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100951

Vancouver

Verhasselt A, Ameye G, Vanhevel J, Tousseyn T, Vets J, Hauben E, et al. Optical Genome Mapping Is a Powerful Diagnostic Tool in Non-Hodgkin Lymphoma. Modern Pathology. 2026. doi:10.1016/j.modpat.2025.100951

BibTeX
@article{Verhasselt2026,
  author = {Verhasselt, Amber and Ameye, Geneviève and Vanhevel, Justine and Tousseyn, Thomas and Vets, Johanna and Hauben, Esther and Meeus, Peter and Bempt, Marlies Vanden and Debackere, Koen and Forsyth, Robert A and Harbers, Luuk and Demeulemeester, Jonas and Michaux, Lucienne and Rack, Katrina and Dewaele, Barbara and De Bie, Jolien},
  title = {Optical Genome Mapping Is a Powerful Diagnostic Tool in Non-Hodgkin Lymphoma},
  journal = {Modern Pathology},
  year = {2026},
  doi = {10.1016/j.modpat.2025.100951}
}
Kostenlos starten →